However, a major hurdle for applying β3-AR agonists to the treatment of obesity is that, besides the poor bioavailability, pharmacological β3-AR activation at an effective dose to achieve thermogenesis inevitably increases blood pressure as well8,9. Here, ADRB3 is linked to obesity disorder.